JP7622019B2 - インターロイキン－３４を標的とする化合物及び方法 - Google Patents

インターロイキン－３４を標的とする化合物及び方法 Download PDF

Info

Publication number
JP7622019B2
JP7622019B2 JP2022172479A JP2022172479A JP7622019B2 JP 7622019 B2 JP7622019 B2 JP 7622019B2 JP 2022172479 A JP2022172479 A JP 2022172479A JP 2022172479 A JP2022172479 A JP 2022172479A JP 7622019 B2 JP7622019 B2 JP 7622019B2
Authority
JP
Japan
Prior art keywords
antibody
disease
seq
human
tau
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2022172479A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023067832A (ja
Inventor
シェディド，マルシオ
エス フライシャー，アダム
ブリタニー ラナン，メーガン
ロー，アルバート
ミンタン，マーク
エイチ オブング，ビクター
エリザベス レインズ，サラ
ランドール，ザ セカンド シムズ，ジョン
ディクソン スコラ，アンドリュー
エリザベス ウォルシュ，ロビン
アン ウエスト，エリザベス
イェ，ミン
Original Assignee
イーライ リリー アンド カンパニー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by イーライ リリー アンド カンパニー filed Critical イーライ リリー アンド カンパニー
Publication of JP2023067832A publication Critical patent/JP2023067832A/ja
Priority to JP2024066552A priority Critical patent/JP2024091777A/ja
Priority to JP2025005276A priority patent/JP2025063187A/ja
Application granted granted Critical
Publication of JP7622019B2 publication Critical patent/JP7622019B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G01N33/6869—Interleukin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G01N2333/54—Interleukins [IL]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2022172479A 2021-10-29 2022-10-27 インターロイキン－３４を標的とする化合物及び方法 Active JP7622019B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2024066552A JP2024091777A (ja) 2021-10-29 2024-04-17 インターロイキン－３４を標的とする化合物及び方法
JP2025005276A JP2025063187A (ja) 2021-10-29 2025-01-15 インターロイキン－３４を標的とする化合物及び方法

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202163273216P 2021-10-29 2021-10-29
US63/273,216 2021-10-29

Related Child Applications (2)

Application Number Title Priority Date Filing Date
JP2024066552A Division JP2024091777A (ja) 2021-10-29 2024-04-17 インターロイキン－３４を標的とする化合物及び方法
JP2025005276A Division JP2025063187A (ja) 2021-10-29 2025-01-15 インターロイキン－３４を標的とする化合物及び方法

Publications (2)

Publication Number Publication Date
JP2023067832A JP2023067832A (ja) 2023-05-16
JP7622019B2 true JP7622019B2 (ja) 2025-01-27

Family

ID=84367272

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2022172479A Active JP7622019B2 (ja) 2021-10-29 2022-10-27 インターロイキン－３４を標的とする化合物及び方法
JP2024066552A Pending JP2024091777A (ja) 2021-10-29 2024-04-17 インターロイキン－３４を標的とする化合物及び方法
JP2025005276A Pending JP2025063187A (ja) 2021-10-29 2025-01-15 インターロイキン－３４を標的とする化合物及び方法

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2024066552A Pending JP2024091777A (ja) 2021-10-29 2024-04-17 インターロイキン－３４を標的とする化合物及び方法
JP2025005276A Pending JP2025063187A (ja) 2021-10-29 2025-01-15 インターロイキン－３４を標的とする化合物及び方法

Country Status (19)

Country Link
US (2) US11976114B2 (https=)
EP (1) EP4423127A1 (https=)
JP (3) JP7622019B2 (https=)
KR (1) KR20240099349A (https=)
CN (1) CN118475610A (https=)
AR (1) AR127484A1 (https=)
AU (1) AU2022376940A1 (https=)
CA (1) CA3236555A1 (https=)
CL (1) CL2024001303A1 (https=)
CO (1) CO2024005417A2 (https=)
CR (1) CR20240170A (https=)
DO (1) DOP2024000076A (https=)
EC (1) ECSP24032906A (https=)
IL (1) IL312380A (https=)
JO (1) JOP20240103A1 (https=)
MX (1) MX2024005153A (https=)
PE (1) PE20241471A1 (https=)
TW (1) TW202336034A (https=)
WO (1) WO2023076995A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023150483A1 (en) * 2022-02-03 2023-08-10 Eli Lilly And Company Regional tau imaging for diagnosing and treating alzheimer's disease

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2018508467A (ja) 2014-12-19 2018-03-29 ユニヴェルシテ・ドゥ・ナント 抗ｉｌ−３４抗体
JP2018516933A (ja) 2015-06-02 2018-06-28 ジェネンテック， インコーポレイテッド 抗ｉｌ−３４抗体を使用して神経学的疾患を治療するための組成物及び方法
JP2019518783A (ja) 2016-07-01 2019-07-04 イーライ リリー アンド カンパニー 抗Ｎ３ｐＧｌｕアミロイドベータペプチド抗体およびその使用
JP2019525920A (ja) 2016-08-09 2019-09-12 イーライ リリー アンド カンパニー 併用療法
JP2023524515A (ja) 2020-04-30 2023-06-12 イーライ リリー アンド カンパニー インターロイキン－３４を標的とする化合物及び方法

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2320942B1 (en) 2008-07-21 2018-03-14 Probiodrug AG Diagnostic antibody assay
US8795664B2 (en) 2010-06-04 2014-08-05 Georg-August-Universität Göttingen Stiftung Öffentlichen Rechts, Universitätsmedizin Monoclonal antibodies targeting amyloid beta oligomers
WO2012019061A2 (en) * 2010-08-05 2012-02-09 Stem Centrx, Inc. Novel effectors and methods of use
PT3042917T (pt) 2010-08-12 2018-05-02 Lilly Co Eli Anticorpos do péptido beta amilóide anti-n3pglu e seus usos
WO2012136552A1 (en) 2011-04-08 2012-10-11 H. Lundbeck A/S ANTIBODIES SPECIFIC TO PYROGLUTAMATED Αβ
US9161968B2 (en) 2011-04-08 2015-10-20 The Board Of Trustees Of The Leland Stanford Junior University Methods of neuroprotection involving macrophage colony stimulating factor receptor agonists
RU2014136332A (ru) 2012-02-06 2016-03-27 Дженентек, Инк. Композиции и способы применения ингибиторов csf1r
MX2017001293A (es) 2014-07-28 2017-05-23 Nogra Pharma Ltd Metodos y composiciones para diagnosticar y tratar trastornos inflamatorios del intestino.
PL3988117T3 (pl) * 2015-04-13 2025-03-10 Pfizer Inc. Przeciwciała terapeutyczne i ich zastosowania
JOP20170004B1 (ar) 2016-01-15 2022-09-15 Lilly Co Eli الأجسام المضادة لببتيد بيتا النشوي مضاد N3pGlu واستخداماته
TWI705975B (zh) 2017-04-20 2020-10-01 美商美國禮來大藥廠 抗－N3pGlu類澱粉β肽抗體及其用途
WO2019169291A1 (en) 2018-03-02 2019-09-06 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Use of il-34 to treat retinal inflammation and neurodegeneration
MX2021014473A (es) 2019-05-31 2022-01-06 Lilly Co Eli Compuestos y metodos dirigidos a la tau humana.

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2018508467A (ja) 2014-12-19 2018-03-29 ユニヴェルシテ・ドゥ・ナント 抗ｉｌ−３４抗体
JP2018516933A (ja) 2015-06-02 2018-06-28 ジェネンテック， インコーポレイテッド 抗ｉｌ−３４抗体を使用して神経学的疾患を治療するための組成物及び方法
JP2019518783A (ja) 2016-07-01 2019-07-04 イーライ リリー アンド カンパニー 抗Ｎ３ｐＧｌｕアミロイドベータペプチド抗体およびその使用
JP2019525920A (ja) 2016-08-09 2019-09-12 イーライ リリー アンド カンパニー 併用療法
JP2023524515A (ja) 2020-04-30 2023-06-12 イーライ リリー アンド カンパニー インターロイキン－３４を標的とする化合物及び方法

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Immunology Today，1993年，Vol.14, No.6，p.243-246
J. Mol. Biol.，1992年，Vol.224, No.2，p.487-499

Also Published As

Publication number Publication date
AU2022376940A1 (en) 2024-05-02
US20240309082A1 (en) 2024-09-19
JP2024091777A (ja) 2024-07-05
IL312380A (en) 2024-06-01
PE20241471A1 (es) 2024-07-17
EP4423127A1 (en) 2024-09-04
US11976114B2 (en) 2024-05-07
CR20240170A (es) 2024-05-24
CA3236555A1 (en) 2023-05-04
WO2023076995A1 (en) 2023-05-04
JOP20240103A1 (ar) 2024-04-29
MX2024005153A (es) 2024-05-13
AR127484A1 (es) 2024-01-31
ECSP24032906A (es) 2024-05-31
US20230279094A1 (en) 2023-09-07
CL2024001303A1 (es) 2024-08-30
JP2023067832A (ja) 2023-05-16
KR20240099349A (ko) 2024-06-28
JP2025063187A (ja) 2025-04-15
CO2024005417A2 (es) 2024-05-30
TW202336034A (zh) 2023-09-16
CN118475610A (zh) 2024-08-09
DOP2024000076A (es) 2024-06-16

Similar Documents

Publication Publication Date Title
WO2021222025A1 (en) Compounds and methods targeting interleukin-34
JP2025063187A (ja) インターロイキン－３４を標的とする化合物及び方法
JP7823186B2 (ja) インターロイキン－３４を標的とする化合物及び方法
JP7780010B2 (ja) インターロイキン－３４を標的とする化合物及び方法
JP7815431B2 (ja) インターロイキン－３４を標的とする化合物及び方法
BR112024008165B1 (pt) Anticorpos direcionados à interleucina-34 e composições que os compreendem
BR122024012949B1 (pt) Ácidos nucleicos, vetores, processos para preparar anticorpos, e método para determinação no nível de il-34 humana em um fluido corporal
BR122025007149A2 (pt) Anticorpos direcionados à interleucina-34 e composições que os compreendem
BR122024012949A2 (pt) Anticorpos direcionados à interleucina-34, composições que os compreendem, usos dos mesmos, combinações, ácidos nucleicos, vetores, células, processos para preparar anticorpos, e método para determinação no nível de il-34 humana em um fluido corporal

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221115

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20221115

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20231011

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20231017

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20231207

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20240313

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240417

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240611

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240904

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20241217

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20250115

R150 Certificate of patent or registration of utility model

Ref document number: 7622019

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150